Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (3084)	5/27/1999 7:10:00 PM
From: Biomaven	Read Replies (1) \| Respond to of 10280

Mike, Yes, basically it was a gold-rush that pretty much nobody else bothered to join. There are a few other companies that joined in on a small scale - Chiroscience in the UK, and CELG here with a Ritalin isomer. Nowadays big pharma obviously look at the single isomers right away for their new drugs. There are some existing big pharma chiral switches - e.g. by J&J. Astra is going to be bringing out an ICE for omeprazole - the biggest selling drug of all. Big pharma may or may not investigate all the metabolites, though. As was pointed out at the annual meeting, SEPR in its own NCE program hasn't been looking at active metabolites - they just want to get something that is safe and effective and here sooner rather than later. There are still a number of as yet untapped generics and old drugs that the originators never got around to trying to improve. SEPR is still furiously adding to its patent portfolio, although I don't think we can assume that all the SEPR patents will turn out to be significant improvements. Peter